What is Kanabo Group?
Founded in 2017 and headquartered in London, Kanabo Group Plc operates as a sophisticated player in the medical cannabis sector. The company distinguishes itself through a dual-focus model: the research and development of high-quality cannabis-derived therapeutic solutions and the distribution of non-tetrahydrocannabinol alternatives for the growing cannabidiol consumer base. By positioning itself as a B2B service provider, Kanabo effectively bridges the gap between complex pharmaceutical research and accessible patient care. Its operational footprint, which spans multiple European jurisdictions, allows the firm to navigate the intricate regulatory environments of the continent while maintaining a consistent brand identity centered on health-focused applications of cannabis compounds.
How much funding has Kanabo Group raised?
Kanabo Group has raised a total of $3.1M across 1 funding round:
Other Financing Round
$3.1M
Other Financing Round (2023): $3.1M, investors not publicly disclosed
Key Investors in Kanabo Group
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Kanabo Group?
Looking ahead, the infusion of capital is expected to accelerate Kanabo Group's research initiatives and enhance its distribution infrastructure. As the company transitions into a more mature phase of its lifecycle, the focus will likely shift toward scaling its proprietary product lines and deepening its penetration into key European healthcare markets. By leveraging this strategic backing, Kanabo is well-positioned to capitalize on the increasing demand for standardized, medical-grade cannabis products. Future growth will depend on the firm's ability to maintain regulatory compliance while simultaneously scaling its supply chain to meet the evolving needs of medical patients and healthcare providers across the region.
See full Kanabo Group company page
